Amica Retiree Medical Trust Sells 150 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Amica Retiree Medical Trust decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,449 shares of the medical research company’s stock after selling 150 shares during the period. Amica Retiree Medical Trust’s holdings in Charles River Laboratories International were worth $452,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after buying an additional 60,497 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after buying an additional 3,738,018 shares during the period. State Street Corp raised its position in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Finally, Sei Investments Co. lifted its position in Charles River Laboratories International by 6.1% during the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company’s stock valued at $124,394,000 after acquiring an additional 38,827 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CRL shares. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a research report on Monday, March 3rd. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $155.00 to $175.00 in a research note on Tuesday, March 4th. Finally, William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Price Performance

CRL stock opened at $158.37 on Thursday. The company has a fifty day simple moving average of $165.00 and a two-hundred day simple moving average of $183.13. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $8.10 billion, a P/E ratio of 1,055.80, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $273.32.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the company earned $2.46 EPS. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).